Innovations for Next-Generation Antibody-Drug Conjugates

Focus on next-generation ADCs for oncology and other diseases Description & analysis of current technological innovations for ADCsADC clinical development in the context of immuno-oncology

Focus on next-generation ADCs for oncology and other diseases Description & analysis of current technological innovations for ADCs ADC clinical development in the context of immuno-oncology

Autorentext

Marc Damelin is Senior Director, Biology at Mersana Therapeutics in Cambridge, Massachusetts. His group is responsible for the discovery of therapeutic ADCs enabled by Mersana's proprietary linker-payload-scaffold technologies. Prior, Marc spent 10 years at Pfizer Inc. in the Oncology Research Unit, where he led ADC discovery teams and ultimately oversaw the ADC portfolio. He received his Ph.D. in Biophysics from Harvard University and conducted postdoctoral research at Columbia University Medical School as a Fellow of the Damon Runyon Cancer Research Foundation.

Zusammenfassung
Focus on next-generation ADCs for oncology and other diseases Description & analysis of current technological innovations for ADCsADC clinical development in the context of immuno-oncology

Inhalt

Chapter 1 Introduction: Motivations for Next-Generation ADCs.- Chapter 2 Combining ADCs with Immuno-oncology Agents.- Chapter 3 Improving the Safety Profile of ADCs.- Chapter 4 Utility of PK-PD Modeling and Simulation to Improve Decision Making for Antibody-Drug Conjugate Development.- Chapter 5 Regulatory Considerations and Companion Diagnostics.- Chapter 6 ADC Process Development and Manufacturing.- Chapter 7 HER2-Targeted ADCs: At the forefront of ADC technology development.- Chapter 8 Next generation payloads for ADCs.- Chapter 9 Delivering more payload: High DAR ADCs.- Chapter 10 Site-Specific Antibody Drug Conjugates.- Chapter 11 Bispecific and Biparatopic Antibody-Drug Conjugates.- Chapter 12 drug conjugates to the tumor microenvironment: Probody Drug Conjugates.- Chapter 13 Antibody-Drug Conjugates: Targeting the Tumor Microenvironment.- Chapter 14 Next Horizons: ADCs Beyond Oncology.